A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

June 4, 2019

Study Completion Date

June 4, 2019

Conditions

ObesityOverweight

Interventions

DRUG

NNC0174-0833

Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.

DRUG

Placebo (NNC0174-0833)

Participants will receive NNC0174-0833 matched placebo subcutaneously.

Trial Locations (1)

Novo Nordisk Investigational Site, Glendale